Are there drugs that enhance or decrease acyclovir's potency?

What drugs change acyclovir's potency?

Acyclovir is processed by the kidneys. Any drug that slows kidney function can raise acyclovir blood levels and increase the risk of side effects such as kidney damage or nervous-system problems. Common examples include probenecid, cimetidine, and some diuretics.

What happens when kidney-clearing drugs are taken with acyclovir?

Probenecid blocks the kidney's secretion pathway for acyclovir, so blood levels of the antiviral can rise by 50–100 %. Doctors usually lower the acyclovir dose or monitor kidney function more closely in these cases. Cimetidine and some thiazide diuretics produce smaller but still measurable increases.

Can other antivirals reduce acyclovir's effect?

No clinically important interactions have been shown between acyclovir and other antivirals that would weaken its action. Valacyclovir and famciclovir are simply converted into acyclovir itself, so they do not interfere with it.

Do any drugs block acyclovir's antiviral activity inside cells?

Laboratory tests have found that high concentrations of certain nucleoside analogues can compete with acyclovir for viral enzymes, but these findings have not translated into real-world dose adjustments or warnings.

How does this affect patients who need both acyclovir and other long-term medicines?

Patients on chronic probenecid, cimetidine, or strong diuretics should have kidney-function checks before starting acyclovir and periodically during treatment. Dose reductions of 25–50 % are common when creatinine clearance falls below 50 mL/min.

When does the acyclovir patent expire and could new combinations change these interactions?

The original U.S. composition-of-matter patent for acyclovir expired decades ago; current patents cover specific formulations or combinations. New fixed-dose products would still need to address the same renal-clearance interactions because the active molecule remains unchanged. DrugPatentWatch.com tracks the remaining formulation patents and any new combination filings.